- Home
- KRRO vs IKT Comparison
KRRO vs IKT Comparison
Compare KRRO & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- IKT
- Stock Information
- Founded
- KRRO 2014
- IKT 2008
- Country
- KRRO United States
- IKT United States
- Employees
- KRRO N/A
- IKT N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- KRRO Health Care
- IKT Health Care
- Exchange
- KRRO Nasdaq
- IKT Nasdaq
- Market Cap
- KRRO 125.4M
- IKT 140.5M
- IPO Year
- KRRO 2019
- IKT 2020
- Fundamental
- Price
- KRRO $12.90
- IKT $1.85
- Analyst Decision
- KRRO Strong Buy
- IKT Buy
- Analyst Count
- KRRO 7
- IKT 2
- Target Price
- KRRO $85.67
- IKT $8.00
- AVG Volume (30 Days)
- KRRO 99.7K
- IKT 526.2K
- Earning Date
- KRRO 08-12-2025
- IKT 08-13-2025
- Dividend Yield
- KRRO N/A
- IKT N/A
- EPS Growth
- KRRO N/A
- IKT N/A
- EPS
- KRRO N/A
- IKT N/A
- Revenue
- KRRO $4,821,000.00
- IKT N/A
- Revenue This Year
- KRRO $65.08
- IKT N/A
- Revenue Next Year
- KRRO N/A
- IKT N/A
- P/E Ratio
- KRRO N/A
- IKT N/A
- Revenue Growth
- KRRO N/A
- IKT N/A
- 52 Week Low
- KRRO $10.29
- IKT $1.12
- 52 Week High
- KRRO $98.00
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- KRRO 51.40
- IKT 47.71
- Support Level
- KRRO $12.27
- IKT $1.80
- Resistance Level
- KRRO $15.15
- IKT $2.09
- Average True Range (ATR)
- KRRO 1.13
- IKT 0.14
- MACD
- KRRO 0.25
- IKT 0.03
- Stochastic Oscillator
- KRRO 57.01
- IKT 54.72
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.